

Sabine Kasimir-Bauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6262678/publications.pdf>

Version: 2024-02-01

87
papers

4,002
citations

172457

29
h-index

123424

61
g-index

89
all docs

89
docs citations

89
times ranked

4811
citing authors

#	ARTICLE	IF	CITATIONS
1	Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2009, 11, R46.	5.0	658
2	HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 403-412.	2.5	330
3	Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. <i>Breast Cancer Research</i> , 2012, 14, R15.	5.0	262
4	Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. <i>Breast Cancer Research</i> , 2009, 11, R59.	5.0	217
5	Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 581-590.	2.5	198
6	Prognostic impact of circulating tumor cells assessed with the CellSearch System [®] and AdnaTest Breast [®] in metastatic breast cancer patients: the DETECT study. <i>Breast Cancer Research</i> , 2012, 14, R118.	5.0	160
7	Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. <i>Gynecologic Oncology</i> , 2011, 122, 356-360.	1.4	127
8	ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance. <i>Clinical Chemistry</i> , 2014, 60, 1282-1289.	3.2	101
9	Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes. <i>Translational Research</i> , 2019, 205, 77-91.	5.0	98
10	Molecular Profiling and Prognostic Relevance of Circulating Tumor Cells in the Blood of Ovarian Cancer Patients at Primary Diagnosis and After Platinum-Based Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 822-830.	2.5	97
11	Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy. <i>Oncotarget</i> , 2018, 7, e1376153.	4.6	86
12	The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients. <i>Human Immunology</i> , 2016, 77, 791-799.	2.4	77
13	Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. <i>Breast Cancer Research</i> , 2016, 18, 20.	5.0	72
14	EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy. <i>Oncotarget</i> , 2017, 8, 48820-48831.	1.8	72
15	Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. <i>International Journal of Cancer</i> , 2011, 128, 2572-2580.	5.1	71
16	Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 522.	2.6	71
17	Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 186-197.	2.3	65
18	RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients. <i>Clinical Chemistry</i> , 2018, 64, 1054-1062.	3.2	55

#	ARTICLE	IF	CITATIONS
19	Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 107, 331-338.	1.4	53
20	Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. <i>Breast Cancer Research</i> , 2009, 11, R71.	5.0	53
21	<i>RASSF1A</i> promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. <i>Oncotarget</i> , 2017, 8, 21429-21443.	1.8	51
22	Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer. <i>Clinical Chemistry</i> , 2017, 63, 1585-1593.	3.2	45
23	Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R20.	5.0	42
24	ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 150, 355-360.	1.4	42
25	Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1015.	2.8	42
26	ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer. <i>Oncotarget</i> , 2017, 8, 24303-24313.	1.8	38
27	LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. <i>BMC Cancer</i> , 2012, 12, 325.	2.6	37
28	Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer. <i>BMC Cancer</i> , 2019, 19, 120.	2.6	37
29	Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. <i>Oncotarget</i> , 0, 7, 41677-41690.	1.8	36
30	Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 497-509.	5.4	31
31	Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1106.	3.7	30
32	The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 93-104.	2.5	28
33	Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1369-1378.	7.0	28
34	The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. <i>Scientific Reports</i> , 2019, 9, 2318.	3.3	27
35	Circulating Tumor Cells as Markers for Cancer Risk Assessment and Treatment Monitoring. <i>Molecular Diagnosis and Therapy</i> , 2009, 13, 209-215.	3.8	26
36	Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer. <i>Cancers</i> , 2019, 11, 238.	3.7	26

#	ARTICLE	IF	CITATIONS
37	Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?. <i>Scientific Reports</i> , 2016, 6, 26355.	3.3	25
38	Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. <i>Anticancer Research</i> , 2011, 31, 3623-8.	1.1	25
39	Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients. <i>Cells</i> , 2021, 10, 212.	4.1	24
40	Circulating tumor cells in breast cancer. <i>Clinica Chimica Acta</i> , 2013, 423, 39-45.	1.1	22
41	Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer. <i>Genome Medicine</i> , 2021, 13, 85.	8.2	21
42	Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2233-2238.	2.5	20
43	Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX [®] , clinicopathological markers and tumor cell dissemination in the blood and bone marrow. <i>Molecular and Clinical Oncology</i> , 2013, 1, 1049-1054.	1.0	18
44	HLA-G 3' untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 5407.	3.3	18
45	Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1389-1395.	2.5	18
46	Combinatorial Power of cfDNA, CTCs and EVs in Oncology. <i>Diagnostics</i> , 2022, 12, 870.	2.6	18
47	Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1658.	2.8	17
48	Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 1084.	3.7	17
49	Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. <i>Scientific Reports</i> , 2017, 7, 17307.	3.3	16
50	Localization of PD-L1 on single cancer cells by iSERS microscopy with Au/Au core/satellite nanoparticles. <i>Journal of Biophotonics</i> , 2020, 13, e201960034.	2.3	15
51	6-Color/1-Target Immuno-SERS Microscopy on the Same Single Cancer Cell. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 32321-32327.	8.0	15
52	High serum levels of periostin are associated with a poor survival in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 515-524.	2.5	15
53	iSERS microscopy guided by wide field immunofluorescence: analysis of HER2 expression on normal and breast cancer FFPE tissue sections. <i>Analyst, The</i> , 2016, 141, 5113-5119.	3.5	14
54	Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 3117-3128.	1.1	14

#	ARTICLE	IF	CITATIONS
55	Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 8405-8416.	3.6	13
56	Changes in the Blood Serum Levels of the Costimulatory Soluble B7-4 Molecule in Pregnant Women During the Peripartal Phase. <i>American Journal of Reproductive Immunology</i> , 2015, 74, 209-215.	1.2	12
57	Prognostic relevance of the AQP5 \sim 1364C>A polymorphism in primary breast cancer. <i>Molecular Medicine Reports</i> , 2009, 2, 645-50.	2.4	11
58	Serum concentrations of soluble B7-4 in early pregnancy are elevated in women with preterm premature rupture of fetal membranes. <i>American Journal of Reproductive Immunology</i> , 2016, 76, 149-154.	1.2	11
59	Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies. <i>Breast Care</i> , 2020, 15, 470-480.	1.4	11
60	Association of the AA genotype of the BCL2 (\sim 938C>A) promoter polymorphism with better survival in ovarian cancer. <i>International Journal of Biological Markers</i> , 2009, 24, 223-229.	1.8	10
61	CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989575.	3.2	10
62	Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2022, 14, 4.	3.7	10
63	Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 87-92.	2.5	9
64	Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer. <i>Molecular Medicine Reports</i> , 2017, 15, 2957-2968.	2.4	9
65	Loss of heterozygosity proximal to the <i>M6P/IGF2R</i> locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 598-605.	2.8	7
66	Systematic Evaluation of HLA-G 3'UTR Untranslated Region Variants in Locally Advanced, Non-Metastatic Breast Cancer Patients: UTR-1, 2 or UTR-4 are Predictors for Therapy and Disease Outcome. <i>Frontiers in Immunology</i> , 2021, 12, 817132.	4.8	7
67	Detection of circulating trophoblast particles in maternal blood using density gradient centrifugation in preeclampsia and in normotensive pregnancies. <i>Hypertension in Pregnancy</i> , 2016, 35, 323-329.	1.1	6
68	Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. <i>BMC Cancer</i> , 2018, 18, 541.	2.6	6
69	Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1159-1174.	2.5	6
70	Multimodality in liquid biopsy: does a combination uncover insights undetectable in individual blood analyses?. <i>Laboratoriums Medizin</i> , 2022, 46, 255-264.	0.6	6
71	Intraindividual right-left comparison of sonographic features in polycystic ovary syndrome (PCOS) diagnosis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 181, 124-129.	1.1	5
72	Development and Validation of Multiplex Liquid Bead Array Assay for the Simultaneous Expression of 14 Genes in Circulating Tumor Cells. <i>Analytical Chemistry</i> , 2019, 91, 3443-3451.	6.5	5

#	ARTICLE	IF	CITATIONS
73	Image-Based Identification and Genomic Analysis of Single Circulating Tumor Cells in High Grade Serous Ovarian Cancer Patients. <i>Cancers</i> , 2021, 13, 3748.	3.7	4
74	Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPAArray, a HER2-FISH workflow. <i>Breast Cancer</i> , 2022, 29, 487-497.	2.9	4
75	Definition and Independent Validation of a Proteomic-Classifer in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 2519.	3.7	3
76	Minimal residual cancer and its clinical relevance. <i>Current Breast Cancer Reports</i> , 2009, 1, 198-206.	1.0	2
77	A proposal for score assignment to characterize biological processes from mass spectral analysis of serum. <i>Clinical Mass Spectrometry</i> , 2020, 18, 13-26.	1.9	2
78	Detection of disseminated tumor cells in bone marrow as an independent prognostic factor in primary ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5042-5042.	1.6	2
79	In Early Breast Cancer, the Ratios of Neutrophils, Platelets and Monocytes to Lymphocytes Significantly Correlate with the Presence of Subsets of Circulating Tumor Cells but Not with Disseminated Tumor Cells. <i>Cancers</i> , 2022, 14, 3299.	3.7	2
80	Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects. <i>Archives of Gynecology and Obstetrics</i> , 2015, 292, 1367-1372.	1.7	1
81	Detection of disseminated tumor cells in the bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22032-e22032.	1.6	1
82	Serum HER2 in the context of circulating tumor cells in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10599-10599.	1.6	1
83	Clinical relevance of VEGF-receptor status in primary ovarian cancer: A pilot study for future biomarker analyses.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5556-5556.	1.6	0
84	Serum mass spectrometry analysis in primary ovarian cancer (OC) treated with surgery and adjuvant chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5575-5575.	1.6	0
85	Evaluation of risk recurrence in early breast cancer assessed by Oncotype DX and tumor cell dissemination to blood and bone marrow.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11516-e11516.	1.6	0
86	Single nucleotide polymorphisms of the EpCAM-coding gene <i>TACSTD1</i> in patients with ovarian cancer and their potential implications in clinical practice.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16515-e16515.	1.6	0
87	Inter-laboratory evaluation of a novel DEPAArray-HER2 FISH assay.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12506-e12506.	1.6	0